主要文件

查看所有文档

I5159

咪喹莫特

Name: 咪喹莫特
Brand: SIGMA

≥98% (HPLC), solid, caspase 3 activator

别名:

1-（2-甲基丙基）-1 H -咪唑 [4,5- c ] 喹啉-4-胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₄H₁₆N₄

化学文摘社编号:

99011-02-6

分子量:

240.30

UNSPSC Code:

12352200

PubChem Substance ID:

24724516

NACRES:

NA.77

MDL number:

MFCD00866946

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

咪喹莫特, ≥98% (HPLC), solid

Quality Level

100

assay

≥98% (HPLC)

form

solid

solubility

H₂O: <2 mg/mL, DMSO: 4 mg/mL (warming to 60 °C for 15 minutes)

SMILES string

CC(C)Cn1cnc2c(N)nc3ccccc3c12

InChI

1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)

InChI key

DOUYETYNHWVLEO-UHFFFAOYSA-N

Gene Information

human ... TLR7(51284)

说明

General description

Imiquimod is a toll-like receptor (TLR)-7/8 agonist.

Application

Imiquimod has been used as TLR7 agonist for TLR7 agonist enhancement studies. It has also been used as an NLR family, pyrin domain containing 3 (NLRP3) stimulant to treat NLRP3-FL-Btn and FLAG-ASC-FL.

Biochem/physiol Actions

Imiquimod helps to induce the innate cutaneous immunity and the cellular arm of the adaptive immune response.

咪喹莫特是半胱天冬酶 3 激活剂，可直接诱导半胱天冬酶 3 裂解为活性半胱天冬酶 3。咪喹莫特在体内 诱导基底细胞癌凋亡 。其抗肿瘤活性与诱导细胞凋亡有关。咪喹莫特具有抗血管生成、抗炎、抗病毒活性。咪喹莫特还可作为免疫应答调节剂，诱导多种细胞因子和趋化因子的分泌。

咪喹莫特是半胱天冬酶 3 激活剂，可直接诱导半胱天冬酶 3 裂解为活性半胱天冬酶 3。咪喹莫特在体内可诱导细胞凋亡，并作为一种免疫调节剂，具有抗病毒和抗炎特性。

Features and Benefits

This compound is featured on the Caspases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Still not finding the right product?

Explore all of our products under 咪喹莫特

pictograms

GHS06

signalword

Danger

hcodes

H301,H315,H319

pcodes

P264 - P270 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.

Aimée H M M Arits et al.

The Lancet. Oncology, 14(7), 647-654 (2013-05-21)

Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments, such as photodynamic therapy or topical creams. Photodynamic therapy is considered the preferable treatment, although this has not been previously tested in a randomised control trial. We assessed the

Topical imiquimod is and effective and safe drug for molluscum contagiosum in children

Badavanis G, et al.

Acta Dermatovenerologica Croatica, 25(2), 164-164 (2017)

IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells.

Ryutaro Yoshiki et al.

The Journal of investigative dermatology, 134(7), 1912-1921 (2014-02-27)

Psoriasis is a common chronic inflammatory skin disease that involves dysregulated interplay between immune cells and keratinocytes. Recently, it has been reported that IL-23 induces CCR6+ γδ T cells, which have the pivotal role in psoriasis-like skin inflammation in mice

查看所有相关文献

全球贸易项目编号

货号	GTIN
I5159-200MG	04061833857182